WuXi

WuXi AppTec acquires ResearchPoint Global

Friday, October 20, 2017

WuXi AppTec, a global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired ResearchPoint Global (RPG), a U.S.-based CRO with expertise spanning across all major therapeutic areas. Upon the closing of this acquisition, RPG will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing better clinical development services. The acquisition underscores a strategic step forward to expand WuXi’s clinical research capabilities in the U.S. and around the world, further strengthening WuXi’s integrated R&D capability platform.

[Read More]

WuXi AppTec acquires HD Biosciences

Friday, January 20, 2017

WuXi AppTec, a global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired HD Biosciences (HDB), a biology-focused preclinical drug discovery CRO. After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.

[Read More]

AbbVie, Genomics Medicine Ireland and WuXi NextCODE partner

Monday, January 9, 2017

AbbVie, a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland (GMI), and WuXi NextCODE, a global contract genomics organization, has announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide. Financial terms were not disclosed.

[Read More]

Concept Life Sciences Groups expands to the U.S

Tuesday, June 28, 2016

The Concept Life Sciences Group, a group created following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited and Resource & Environmental Consultants Limited, has launched its services in the U.S. The integrated group, which further expanded following the acquisition of CXR Biosciences and Agenda1 Analytical Services in 2015, offers a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries.

[Read More]

WuXi, Huawei launch the China Precision Medicine Cloud

Thursday, May 26, 2016

Huawei, a global information and communications technology provider, and WuXi AppTec, a global open-access R&D platform, have launched the China Precision Medicine Cloud. This platform brings together three unique elements: Huawei’s capabilities and national network for cloud computing, the medical innovation expertise of WuXi AppTec and the experience of its subsidiary WuXi NextCODE in organizing, mining and sharing genomics big data.

[Read More]

Juno, WuXi launch JW Biotechnology in China

Monday, April 11, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and WuXi AppTec, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd‘s mission is to build China’s  cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. 

[Read More]